#VisualAbstract: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive Non-Small Cell Lung Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: nsclc
#VisualAbstract: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC)
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
#VisualAbstract: Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
Immunotherapy plus stereotactic radiotherapy improves outcomes in early-stage lung cancer
1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR ...
Tumor Treating Fields vs Standard Therapy in Treatment-Resistant Metastatic NSCLC
1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with an HR of ...
Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy
1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and ...
#VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer
1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in the chemotherapy group. 2. Patients ...
#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer
1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...
#VisualAbstract: Lobar vs Sublobar Resection for Peripheral Stage IA NSCLC
1. The 5-year disease-free survival, overall survival, and recurrence rates were similar in both lobar vs sublobar resections for patients ...
#VisualAbstract: Adjuvant pembrolizumab increased disease-free survival in completely resected, PD-L1 unselected non-small-cell lung cancer patients
1. Adjuvant pembrolizumab significantly improved disease-free survival in comparison to placebo in PD-L1 unselected non-small-cell lung cancer patients who underwent ...
